The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

Published:2020-07-03 Issue:1 Volume:18 Page:
ISSN:1477-7819
Container-title:World Journal of Surgical Oncology
language:en
Short-container-title:World J Surg Onc

Author:

Chen Jingjie,Li Shengnan,Yao Qigu,Du Nannan,Fu Xiaojun,Lou Yuanmei,Wang Mengru,Mao Feiyan,Mao Danyi,Khadaroo Parikshit Asutosh,Tang Yingying

Funder

Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province

Ningbo Clinical Research Center for Digestive System Tumors

Oncology Key Special Subject of Ningbo

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1186/s12957-020-01933-5.pdf

Reference62 articles.

1. Rowshanravan B, Halliday N: CTLA-4: a moving target in immunotherapy. 2018, 131(1):58-67.

2. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunological reviews. 2008;224:166–82.

3. Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, Stahl ML, Seehra J, Somers WS, Mosyak L. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature. 2001;410(6828):608–11.

4. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science (New York, NY). 2008;322(5899):271–5.

5. Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol. 2019.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ELISA assay for the quantification of ipilimumab in human serum, plasma, milk, and cerebrospinal fluid;Journal of Pharmaceutical and Biomedical Analysis;2024-08

2. Navigating immunotherapy for ovarian cancer: current landscape and future perspectives;Journal of Cancer Metastasis and Treatment;2024-06-26

3. Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1;Cancers;2024-03-21

4. Comprehensive Analyses of PANoptosome with Potential Implications in Cancer Prognosis and Immunotherapy;Biochemical Genetics;2024-03-04

5. Volumetric growth rate of incidentally found meningiomas on immunotherapy;Journal of Neuro-Oncology;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3